Cytomegalovirus pUL97 Kinase Inhibitor [EPC]

2469 reported adverse events

Drugs of this class: MARIBAVIR

These side effects are most commonly reported by patients taking drugs of the Cytomegalovirus pUL97 Kinase Inhibitor [EPC] class:

# Side effect Count
0 DEATH 317
1 DYSGEUSIA 268
2 TASTE DISORDER 229
3 HOSPITALISATION 223
4 OFF LABEL USE 206
5 CYTOMEGALOVIRUS INFECTION 189
6 DRUG INEFFECTIVE 187
7 DRUG RESISTANCE 184
8 FATIGUE 176
9 CYTOMEGALOVIRUS INFECTION REACTIVATION 156
See all common reactions for Cytomegalovirus pUL97 Kinase Inhibitor [EPC]

Drugs of the Cytomegalovirus pUL97 Kinase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 LUNG DISEASE INFECTIVE EXACERBATION 10 0.3704
1 AUTOIMMUNE PANCYTOPENIA 10 0.1099
2 VIRAL LOAD ABNORMAL 10 0.0571
3 VIRAL LOAD DECREASED 8 0.0548
4 DRUG RESISTANCE MUTATION 7 0.0393
5 CYTOMEGALOVIRUS INFECTION REACTIVATION 156 0.0353
6 VIRAL LOAD INCREASED 128 0.0329
7 CYTOMEGALOVIRUS TEST POSITIVE 58 0.0325
8 PARVOVIRUS INFECTION 13 0.0322
9 CYTOMEGALOVIRUS GASTROINTESTINAL INFECTION 9 0.0302
See all enriched reactions for Cytomegalovirus pUL97 Kinase Inhibitor [EPC]